Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Low-grade Glioma Market to Boost at a CAGR of 3.4% by 2032 | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

21 Sep, 2022, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

Presently, the low-grade glioma market in the United States is driven by current treatment practices, mainly off-label treatments. The expected launch of emerging therapies during the forecast period is expected to drive the upcoming low-grade glioma market.

LAS VEGAS, Sept. 21, 2022 /PRNewswire/ -- DelveInsight's Low-grade glioma Market Insights report includes a comprehensive understanding of current treatment practices, low-grade glioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Low-grade Glioma Market Report

  • As per DelveInsight analysis, the low-grade glioma market size in the 7MM was approximately USD 969 million in 2021.
  • As per the estimates, the total low-grade glioma incident population in the 7MM was approximately 9K in 2021. 
  • Leading low-grade glioma companies such as Novartis, Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly, and Company, and others are developing novel drugs that can be available in the low-grade glioma market in the upcoming years.
  • The low-grade glioma therapies in the pipeline include Tovorafenib (DAY101), AB-218, BGB-290, Mirdametinib, Vorasidenib (AG-881), Infigratinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, Pemazyre (Pemigatinib), Verzenio, and others.
  • Novartis presented Phase II results from a new, oral targeted therapy combination (Dabrafenib/Trametinib) at the American Society Of Clinical Oncology (ASCO) 2022.
  • In June 2022, Day One Biopharmaceuticals announced positive preliminary data from its pivotal Phase II (FIREFLY-1) study with tovorafenib (DAY101) in children with relapsed low-grade glioma (pLGG).

Discover which therapies are expected to grab major low-grade glioma market share @Low-grade Glioma Market Report

Low-grade Glioma Overview

Low-grade glioma is a diverse group of primary brain tumors that commonly occur in young, otherwise healthy patients and have an indolent course with longer-term survival when compared to high-grade glioma. Furthermore, in this type of brain tumor with a relatively good prognosis and prolonged survival, potential treatment benefits must be carefully weighed against potential treatment-related risks.

Seizures, loss of time, a sense of déjà vu or jamais vu, difficulty speaking and understanding others, episodes of confusion, numbness or weakness, and vision problems are among the low-grade glioma symptoms.

Low-grade-glioma diagnosis is made using a combination of imaging, histopathology, and molecular diagnostic methods. Low-grade-glioma appears as diffuse areas of low attenuation on computed tomography scans.

Low-grade Glioma Epidemiology Segmentation

DelveInsight estimates that there were approximately 9K low-grade glioma incident cases in the 7MM in 2021.

Among the EU5 countries, the incident cases of low-grade glioma were maximum in Germany in 2021.

The low-grade glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Incident Population of Glioma
  • Total Incident Population of Low-grade Glioma
  • Grade-specific Population of Low-grade Glioma
  • Age-specific Population of Low-grade Glioma
  • Type-specific Population of Low-grade Glioma
  • Low-grade Glioma Cases Based on Molecular Alterations
  • Enhancing and Non-enhancing Grade II Glioma cases

Download the report to understand which factors are driving Low-grade Glioma epidemiology trends @Low-grade Glioma Epidemiological Insights

Low-grade Glioma Treatment Market 

Low-grade gliomas are typically treated with surgery, observation, and radiation. Because of the advent of MRI scanning, a "watch and wait" policy with low-grade gliomas may be appropriate on occasion. If seizure disorders are the patient's only symptom, they can be controlled with monovalent or polyvalent anticonvulsant therapy. If the lesion grows, changes radiologically by developing foci of gadolinium enhancement, or symptoms or signs worsen, intervention is usually required.

The palliative low-grade glioma treatment may include surgery, radiation therapy, and chemotherapy. The best low-grade glioma treatment options for each person are determined by various factors, including the tumor's size and location, the extent to which the tumor has grown into the surrounding normal brain tissues, and the affected person's age and overall health.

Recently, in June 2022, Novartis announced that the FDA granted accelerated approval to Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation, who have progressed following prior treatment and have no satisfactory alternative low-grade glioma treatment options.

To know more about low-grade glioma treatment options, visit @Low-grade Glioma Treatment Guidelines

Low-grade Glioma Pipeline Therapies and Key Companies

  • Tovorafenib (DAY101): Day One Biopharmaceuticals
  • AB-218: AnHeart Therapeutics
  • BGB-290: Beigene
  • Mirdametinib: SpringWorks Therapeutics
  • Vorasidenib (AG-881): Servier
  • Infigratinib: Helsinn
  • FT-2102 (Olutasidenib): Forma Therapeutics
  • Vinblastine + Bevacizumab: Hoffmann-La Roche, and others

Learn more about the low-grade glioma therapies in clinical trials @Drugs for Low-grade Glioma Treatment 

Low-grade Glioma Market Dynamics

The dynamics of the low-grade glioma market are anticipated to change in the coming years owing to the improvement in the research and development activities so that the low-grade glioma market will comprise efficient treatment options. Furthermore, the launch of emerging therapies is expected to increase the low-grade glioma market size during the forecast period of 2022–2032.

As low-grade glioma is a rare type of glioma, companies developing treatment options for it can benefit from low-grade glioma market exclusivity, premium pricing, trial subsidies, and other government R&D benefits. 

While newer imaging techniques such as MR spectroscopy (MRS) and positron emission tomography (PET) imaging may improve diagnostic potential, conventional MRI still struggles to distinguish between primary tumors versus metastases and CNS masses, as well as proper progression versus pseudoprogression.

However, there is a lack of a reliable biomarker in the low-grade glioma market that can aid in the diagnosis, patient stratification, recurrence detection, and therapy response. As a result, there is a need for biomarkers that can both overcome the disease's complexity and allow for minimally invasive detection and analysis.

Furthermore, in the case of brain tumors, there is a high trial failure and termination rate in the low-grade glioma market. Additionally, in the current treatment landscape, the high recurrence rate poses a challenge to the low-grade glioma market growth.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Base Year

2021

Market CAGR

3.4 %

Market Size in 2021

USD 969 Million

Key Low-grade Glioma Companies

Novartis, Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly and Company, and others

Key Low-grade Glioma Therapies

Tovorafenib (DAY101), AB-218, BGB-290, Mirdametinib, Vorasidenib (AG-881), Infigratinib, FT-2102 (Olutasidenib), and others

Scope of the Low-grade Glioma Market Report

  • Therapeutic Assessment: Low-grade Glioma current marketed and emerging therapies
  • Low-grade Glioma Market Dynamics: Low-grade Glioma market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Low-grade Glioma Market Access and Reimbursement

Discover more about drugs for Low-grade Glioma in development @Low-grade Glioma Clinical Trials

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

Low-grade Glioma Market Executive Summary

4.

Key Events

5.

SWOT Analysis

6.

Epidemiology and Market Methodology

7.

Low-Grade Glioma Market Overview at a Glance

8.

Disease Background and Overview

9.

Treatment of tumor

10.

Treatment Guidelines

11.

Epidemiology and Patient Population of LGG in the 7MM

12.

Patient Journey

13.

Key Endpoints in Low-grade Glioma

14.

Low-grade Glioma Marketed Drugs

15.

Low-grade Glioma Emerging Drugs

16.

Low-grade Glioma: 7MM Market Analysis

17.

Unmet Needs

18.

Market Access and Reimbursement 

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Low-grade Glioma Epidemiology Forecast

Low-grade Glioma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the low-grade glioma epidemiology trends.

Glioma Market

Glioma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioma companies, including Istari Oncology, Neonc Technologies, Inc., Agios Pharmaceuticals, Basilea Pharmaceutica, among others.

High-grade Glioma Pipeline

High-grade Glioma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key high-grade glioma companies, including PTC Therapeutics, Aadi, Lee's Pharmaceutical, among others.

Malignant Glioma Pipeline

Malignant Glioma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant glioma companies, including Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co, Oblato, Inc., OncoSynergy, Inc, among others.

Recurrent Malignant Glioma Pipeline

Recurrent Malignant Glioma Pipeline Insight – 2022 report provides comprehensive insights into the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent malignant glioma companies, including Bexion Pharmaceuticals, Inc., Merck, Oblato, OncoSynergy, Inc, among others.

Other Trending Reports

Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | CAR-T Pipeline Insight | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Outlook Report | Crows Feet Market Insight | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Additionally, get in touch with our business executive to explore @Healthcare Due Diligence Services 

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging ...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.